OXBT - Oxygen Biotherapeutics, Inc. (NASDAQ) Stock - Page 14 - Stock Market Forum, Penny Stocks, FOREX, NASDAQ, AMEX, NYSE, Live Chat

**BadThad** · #**131** 12-10-2009, 01:30 PM

News:

Quote:

Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
11:08a ET December 4, 2009 (PR NewsWire)
Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the first patient has been enrolled in the company's Phase II-b, dose escalation, clinical trial in Switzerland for use of Oxycyte(TM) emulsion in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

"This trial is of invaluable importance in improving the outcome of patients with severe TBI. We hope to finally prove that there is a safe and effective treatment for this devastating injury," said Chris Stern, company chairman and CEO. "I know that our shareholders have been wondering why it has taken so long to dose the first patient. It has taken longer than expected due to important training and logistical considerations at the trial sites. Those are being resolved on a site-by-site basis and enrollment should now start progressing. I'll go into more detail on that in my blog over the weekend. But I have to emphasize that our main criterion in the trial is safety. We therefore intentionally did not rush enrollment in the early stage. Our early competitors showed us how dangerous it is to rush a trial. We will not do that."

Out of respect for the privacy of the patients and their families, the company will not be disclosing any identifying information about patients in the study or the type of accident that caused the TBI.

The company has named the 128 patient study "Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury" or "STOP TBI". Since study participants will all be emergency cases, it is not possible to predict the precise timing of the flow of patients into the study, which is being supervised by a contract research organization, PFC Pharma Focus AG. The principal investigator is Dr. Michael Reinert of the Department of Neurosurgery at the University Hospital of Berne.

The dose escalation studies will focus on finding the lowest dose of Oxycyte that provides clinical benefit in traumatic brain injury while minimizing adverse effects. Dose levels of Oxycyte will start at 1.0 ml/kg body weight and escalate in steps to 2.0 ml/kg, and 3.0 ml/kg for subsequent patient cohorts. Escalation of dose will only occur after a favorable review of safety data by an independent Data Safety Monitoring Board.

**BadThad** · #**132** 12-15-2009, 04:21 PM

News:

Quote:

Oxygen Biotherapeutics, Inc. Expands Board of Directors
8:30a ET December 14, 2009 (PR NewsWire)
Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced the expansion of the company's board of directors with the addition of Lt. Gen. Ronald R. Blanck, DO, U.S. Army (Ret.). Dr. Blanck is chairman of Martin, Blanck & Associates, a federal health services consulting firm based in Falls Church, Virginia. With his addition, the company board now has nine members.

Dr. Blanck began his military career in 1968 as a medical officer and battalion surgeon in Vietnam. He retired 32 years later as a Lieutenant General and Surgeon General of the U.S. Army and commander of the U.S. Army Medical Command with more than 46,000 military personnel and 26,000 civilian employees throughout the world. During his distinguished military career, Dr. Blanck also served as commander of Walter Reed Medical Center and the North Atlantic Region Medical Command.

After his military service and prior to joining Martin, Blanck & Associates, Dr. Blanck served as the president of the University of North Texas Health Science Center at Fort Worth. As president, Dr. Blanck headed a growing academic health center that includes the Texas College of Osteopathic Medicine, Graduate School of Biomedical Sciences, School of Public Health and School of Health Professions.

"I am very honored that an individual with Ron Blanck's combination of military and medical credentials is coming onto our board of directors, especially as we look toward expanding our efforts in Defense Medicine(TM). As you know, we believe Oxycyte(TM) has the potential to help reduce the long-term brain damage to our forces who are blast injury casualties in Iraq and Afghanistan. His medical expertise and his military contacts should be helpful in our efforts in this area," said Chris Stern, company chairman and CEO.

"Also, this expansion of the board is part of our goal to change the board's structure so that it builds out its majority of independent outside directors, something I believe is important in view to a move to a major exchange listing," said Stern.

**BadThad** · #**133** 01-11-2010, 02:26 PM

Yes!

Quote:

oxygen biotherapeutics, inc. Announces approval for nasdaq listing
3:23p et january 8, 2010 (pr newswire)
oxygen biotherapeutics, inc. (otc bulletin board: Oxbt) announced today that its common stock has been approved for listing on the nasdaq capital market.

"moving up from the otc bulletin board to the nasdaq is a very important milestone for our company," said company chairman and ceo chris j. Stern. "being listed on the nasdaq provides us with greater visibility for our company, more liquidity for our stock and the opportunity to further expand our investor base. I believe that this move will deliver increased value for our shareholders now and down the road."

trading on the nasdaq is excepted to begin next week. The company will announce further details in due course. Prior to the listing change, oxygen biotherapeutics, inc. Shares will continue to trade on the over-the-counter (otc) bulletin board.

**BadThad** · #**134** 01-12-2010, 02:36 PM

Lots of buys today driving the price up to $6.40. I guess people are trying to build up shares before the NASDAQ listing.

**BadThad** · #**135** 01-14-2010, 09:51 AM

News:

Quote:

Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation
12:23p ET January 13, 2010 (PR NewsWire)
Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) chairman and CEO Chris Stern outlined plans for the introduction of new products during a presentation today at the OneMedForum 2010 investor conference in San Francisco.

During the brief presentation, limited by conference organizers to 10 minutes per company, Stern said Oxygen Biotherapeutics, Inc. plans to launch four products in its cosmetics line during 2010. They include an eye cream for fine line wrinkles around the eyes, a face lotion, an improved oxygen concentrate gel, and a perfluorocarbon skin oxygenating liquid -- all based on the company's perfluorocarbon oxygenating technology.

Stern also told the audience that the company has developed and plans to add two veterinary product lines based on Oxycyte(TM). Depending on regulatory approval, the first line could launch this year. It will feature topical wound treatment solutions. That would be followed by an intravenous veterinary product for multiple indications. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

Quote:

NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
1:59p ET January 13, 2010 (PR NewsWire)
Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) announced today that the company's common stock will begin trading on the NASDAQ Capital Market with the opening of trading on Friday, January 15, 2010. The shares will continue to trade under the symbol OXBT.

In addition, company chairman and CEO Chris Stern will be in New York to ring the opening bell at the NASDAQ one week later on Friday, January 22.

**BadThad** · #**136** 01-14-2010, 03:17 PM

Up 10% on low volume to $6.75!

**BadThad** · #**137** 01-22-2010, 01:16 PM

Price holding well on the NASDAQ so far but the volume stinks.

**greencat** · #**138** 01-24-2010, 09:15 PM

This chart not looking healthy. Nice if you picking them at the bottom-wide swings-

OXBT Chart

**BadThad** · #**139** 02-26-2010, 01:23 PM

The volume has been TERRIBLE since moving to NASDAQ! They need to get off their asses and start pumping out some news. They are doing a bad job of promoting the company and releasing news since the change-over. They really do have a lot going for them with oxycyte, but unless the world hears about it the stock is going to be stuck in a rut.

**BadThad** · #**140** 03-29-2010, 09:35 AM

Finally....some news....and it sent the stock up over 50% today!

Quote:

Oxygen Biotherapeutics Now Marketing New Formulation of Dermacyte(TM) Oxygen Concentrate
8:01a ET March 29, 2010 (GlobeNewswire)
Oxygen Biotherapeutics, Inc. (Nasdaq

XBT) today announced that the company has begun distribution for its newly formulated Dermacyte(TM) Oxygen Concentrate for the beauty and skin care market. The over-the-counter product is a scientifically designed perfluorocarbon concentrate to enhance oxygen delivery to skin. As of later this week, retail orders also can be placed on the Dermacyte secure website at DERMACYTE | Oxygen Enriched Beauty for the Skin.

"Inventory of Dermacyte(TM) sold out quickly last fall when it was originally introduced in a market test designed to gauge customer interest and response," said Chris Stern, company chairman and CEO. "The feedback we received from customers was quite positive. We've improved the Dermacyte concentrate to be smoother and more effective. Therefore, we believe that our new cosmetic line has the potential to be a significant financial contributor to our company."

Dermacyte(TM) Oxygen Concentrate is the first product in a broad and diverse cosmetic line currently under development. It uses the company's patented Oxycyte technology, an oxygen carrier scientifically designed to enhance oxygen delivery to tissues such as skin. Some potential benefits of increased oxygenation to the skin include a decrease in the appearance of fine lines, wrinkles and dryness.

Current stock price: $7.10